RBC Capital Reiterates Outperform on Pliant Therapeutics, Maintains $57 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has reiterated his 'Outperform' rating on Pliant Therapeutics (NASDAQ:PLRX), maintaining a price target of $57.
August 08, 2023 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its 'Outperform' rating on Pliant Therapeutics, maintaining a price target of $57.
The reiteration of the 'Outperform' rating by RBC Capital indicates a positive outlook for Pliant Therapeutics. The maintained price target of $57 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100